Capstone Investment Advisors LLC Purchases New Shares in TG Therapeutics, Inc. $TGTX

Capstone Investment Advisors LLC purchased a new position in TG Therapeutics, Inc. (NASDAQ:TGTX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,611 shares of the biopharmaceutical company’s stock, valued at approximately $693,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Bank of America Corp DE raised its position in TG Therapeutics by 71.7% during the first quarter. Bank of America Corp DE now owns 1,461,302 shares of the biopharmaceutical company’s stock valued at $48,544,000 after buying an additional 610,195 shares during the period. Deutsche Bank AG acquired a new stake in TG Therapeutics during the 2nd quarter worth about $12,937,000. Hsbc Holdings PLC boosted its position in TG Therapeutics by 228.7% during the 4th quarter. Hsbc Holdings PLC now owns 146,087 shares of the biopharmaceutical company’s stock worth $4,374,000 after acquiring an additional 101,646 shares during the period. Gibbs Wealth Management grew its stake in TG Therapeutics by 75.3% during the 1st quarter. Gibbs Wealth Management now owns 28,018 shares of the biopharmaceutical company’s stock valued at $931,000 after acquiring an additional 12,032 shares in the last quarter. Finally, Edgestream Partners L.P. purchased a new position in TG Therapeutics during the 1st quarter valued at about $5,593,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on TGTX shares. Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, June 1st. JPMorgan Chase & Co. lifted their price target on TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Bank of America boosted their price target on TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a research note on Tuesday, July 7th. HC Wainwright restated a “buy” rating and issued a $78.00 price objective on shares of TG Therapeutics in a report on Tuesday, August 4th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research report on Wednesday, July 29th. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $63.00.

TG Therapeutics Trading Down 3.2%

TG Therapeutics stock opened at $53.93 on Friday. TG Therapeutics, Inc. has a one year low of $26.76 and a one year high of $59.30. The company’s fifty day moving average price is $53.37 and its two-hundred day moving average price is $41.82. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.27 and a quick ratio of 3.72. The company has a market capitalization of $8.26 billion, a price-to-earnings ratio of 19.68, a PEG ratio of 2.39 and a beta of 1.62.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). The company had revenue of $240.34 million during the quarter, compared to analyst estimates of $229.77 million. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.TG Therapeutics’s quarterly revenue was up 70.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.17 EPS. On average, analysts forecast that TG Therapeutics, Inc. will post 0.92 earnings per share for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.